Trial Profile
Phase II Single-arm Study Evaluating Neo-adjuvant (Pre-radical Radiotherapy) Abiraterone Acetate (Plus Prednisolone) and Gonadotropin-Releasing Hormone (GnRH) Agonist in High Risk Localised Prostate Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- 18 Feb 2023 Results assessing the clinical, radiological and biochemical response achieved by 4 months of neo-adjuvant (NA) combination hormone therapy (HT) comprising abiraterone acetate (AA), prednisolone and gonadotrophin-releasing hormone (GnRH) agonist in treatment-naive high-risk localised prostate carcinoma (HRLPC) prior to radical radiotherapy (RRT) presented at the 2023 Genitourinary Cancers Symposium
- 18 Feb 2021 Status changed from active, no longer recruiting to completed.
- 27 Jul 2020 Planned End Date changed from 1 Oct 2020 to 1 Jan 2021.